Rings Bonded Directly To Each Other In Acid Moiety Patents (Class 560/59)
  • Publication number: 20100286416
    Abstract: The present invention provides the production method of carboxylic acid compound, as shown in Scheme I.
    Type: Application
    Filed: March 26, 2010
    Publication date: November 11, 2010
    Applicant: Japan Tobacco Inc.
    Inventors: Katsuya Matsumoto, Katsuyuki Yokota, Yuko Shinagawa, Teruhiko Inoue
  • Patent number: 7816385
    Abstract: A novel class of dicarboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator -Activated Receptors (PPAR).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 19, 2010
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Per Sauerberg, Lone Jeppesen, Zdenek Polivka, Karel Sindelar
  • Publication number: 20100190107
    Abstract: A cyclic compound shown by the following formula (I):
    Type: Application
    Filed: June 13, 2008
    Publication date: July 29, 2010
    Applicant: Idemitsu Kosan Co. Ltd
    Inventors: Mitsuru Shibata, Takanori Owada, Akinori Yomogita, Takashi Kashiwamura, Masashi Sekikawa, Norio Tomotsu, Hirotoshi Ishii
  • Publication number: 20100184977
    Abstract: Organozinc compounds of the type R1—Ar1—ZnY (1) can be reacted with different functionalized aryl halides R2—Ar2—X (2) in the presence of catalytic amounts of Ni or Fe in a polar solvent or solvent mixture to form polyfunctional biaryles of the type R1—Ar1—Ar2—R2 (3). Organozinc compounds of the type (1) can be represented by the transmetallation reaction of functionalized aryl magnesium halides or lithium aryl compounds with e.g. ZnBr2.
    Type: Application
    Filed: September 12, 2006
    Publication date: July 22, 2010
    Inventors: Paul knochel, Andrei Gavriushin, Christiane Charlotte Kofink, Georg Manolikakes
  • Patent number: 7745099
    Abstract: A photosensitive compound as a molecular resist whose size is smaller than conventional polymer for photoresist, and which can form a nano assembly, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 50 to 5000 weight parts of an organic solvent with respect to 100 weight parts of the photosensitive compound. In the formula, n is the number of repetition of an isopropyl oxide (—CH(CH3)CH2O—) monomer, and is an integer of 1 to 40, and R is an alkyl group of 1 to 20 carbon atoms or a cycloalkyl group of 3 to 20 carbon atoms.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: June 29, 2010
    Assignee: Dongjin Semichem Co., Ltd.
    Inventors: Jung-Woo Kim, Deog-Bae Kim, Jae-Hyun Kim
  • Patent number: 7737176
    Abstract: The invention relates to compounds of the formula I: and to the pharmaceutically acceptable salts thereof, to processes for the preparation of them and to pharmaceutical compositions comprising them, which are useful especially for the treatment and prevention of dyslipidaemia, atherosclerosis and diabetes.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: June 15, 2010
    Assignee: Merck Patent GmbH
    Inventors: Michel Brunet, Jean-Jacques Zeiller, Gérard Ferrand, Yves Bonhomme
  • Publication number: 20100144806
    Abstract: A compound of the formula (I): wherein each symbol is as defined in the description, a salt s thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonist activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
    Type: Application
    Filed: July 28, 2006
    Publication date: June 10, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro
  • Patent number: 7674922
    Abstract: The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R8, R9, and R10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R1, R2, and R3 defined herein.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: March 9, 2010
    Assignee: Albany Molecular Research, Inc.
    Inventors: David C. Burdick, Steven J. Collier, Frédéric Jos, Betina Biolatto, Bernhard J. Paul, Harold Meckler, Mark A. Helle, Alicia J. Habershaw
  • Publication number: 20100041657
    Abstract: The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.
    Type: Application
    Filed: May 11, 2006
    Publication date: February 18, 2010
    Applicant: NOVO NORDICK A/S
    Inventors: Preben Houlberg Olesen, Holger Claus Hansen, Lise Brown Christiansen, Flemming Elmelund Nielsen, Anders Klarskov Petersen
  • Publication number: 20090323011
    Abstract: Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed.
    Type: Application
    Filed: June 23, 2009
    Publication date: December 31, 2009
    Applicant: Transitions Optical, Inc.
    Inventors: Meng He, Anil Kumar, Jiping Shao, Xiao-Man Dai, Ruisong Xu
  • Publication number: 20090326186
    Abstract: Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed.
    Type: Application
    Filed: June 27, 2008
    Publication date: December 31, 2009
    Applicant: TRANSITIONS OPTICAL, INC.
    Inventors: Meng He, Anil Kumar, Jiping Shao, Xiao-Man Dai, Ruisong Xu
  • Patent number: 7618690
    Abstract: A liquid crystal compound represented by the formula CH2?CR1—COO-(L)k-E1-E2-E3-E4-R2 wherein R1: a hydrogen atom or a methyl group; R2: a C1-8 alkyl group; k: 0 or 1; L: —(CH2)pO— or —(CH2)q— (wherein each of p and q which are independent of each other, is an integer of from 2 to 8); E1: a 1,4-phenylene group; E2, E3, E4: each independently a 1,4-phenylene group or a trans-1,4-cyclohexylene group and at least one of E2 and E3 is a trans-1,4-cyclohexylene group, provided that the 1,4-phenylene group and trans-1,4-cyclohexylene group in E1 to E4, may be such that a hydrogen atom bonded to a carbon atom in each group may be substituted by a fluorine atom, a chlorine atom or a methyl group. To provide a novel liquid crystal compound for preparing an optical element which can exhibit a proper Rd value depending upon usable wavelength and application and which is excellent in durability against a blue laser beam.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: November 17, 2009
    Assignee: Asahi Glass Company, Limited
    Inventors: Hiromichi Nagayama, Yuriko Kaida, Kara Yoshida
  • Publication number: 20090275646
    Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.
    Type: Application
    Filed: April 21, 2009
    Publication date: November 5, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
  • Publication number: 20090246684
    Abstract: A photosensitive compound as a molecular resist whose size is smaller than conventional polymer for photoresist, and which can form a nano assembly, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 50 to 5000 weight parts of an organic solvent with respect to 100 weight parts of the photosensitive compound. In the formula, n is the number of repetition of an isopropyl oxide (—CH(CH3)CH2O—) monomer, and is an integer of 1 to 40, and R is an alkyl group of 1 to 20 carbon atoms or a cycloalkyl group of 3 to 20 carbon atoms.
    Type: Application
    Filed: November 13, 2008
    Publication date: October 1, 2009
    Inventors: Jung-Woo KIM, Deong-Bae Kim, Jae-Hyun Kim
  • Publication number: 20090239869
    Abstract: Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.
    Type: Application
    Filed: March 16, 2009
    Publication date: September 24, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Robert M. Burk, Jeremiah H. Nguyen
  • Publication number: 20090233921
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 17, 2009
    Applicant: ALLERGAN, INC.
    Inventor: Yariv Donde
  • Patent number: 7585895
    Abstract: Therapeutic prostaglandin compounds are disclosed herein.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: September 8, 2009
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Robert M. Burk
  • Publication number: 20090087590
    Abstract: Disclosed is an optically anisotropic film comprising at least one compound having a partial structure represented by formula (1): where, each of R1, R2 and R3 independently represent a substituent; X represents a divalent linking group; “A” represents —COO—, —OCO—, or a substituted or non-substituted phenylene group, oxadiazole group or alkynylene group; Z represents a substituted or non-substituted alkyl group or aryl group; each of n1, n2 and n3 represents an integer of 0 to 4; and each of l, m and n represents an integer of 0 to 4.
    Type: Application
    Filed: September 25, 2008
    Publication date: April 2, 2009
    Applicant: FUJIFILM Corporation
    Inventors: Yasuhiro Aiki, Shinichi Morishima
  • Publication number: 20080312321
    Abstract: Therapeutic compounds are disclosed herein.
    Type: Application
    Filed: August 14, 2008
    Publication date: December 18, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Robert M. Burk
  • Patent number: 7442418
    Abstract: The present compound represented by formula(I) CH2?CR1—COO—(L)k-E1-E2-E3-(E4)m-(E5)n-R2??(1) provided that the symbols in the formula have the following meanings: R1: a hydrogen atom or a methyl group; R2: a C1-8 alkyl group; L: —(CH2)pO—, —(CH2)q—, -Cy-COO— (Cy is a trans-1,4-cyclohexylene group), -Cy-OCO—, -E6-(CH2)2—, -E7-CH2O— or -E8-O— (wherein each of p and q which are independent of each other, is an integer of from 2 to 8); E1, E2, E3 E4, E5, E6, E7, E8: each independently a 1,4-pheneylene group or a trans-1,4-cyclohexylene group (provided that at least one of E1, E2 and E3 is a trans-1,4-cyclohexylene group, and in a case where L is -Cy-OCO—, E1 is a trans-1,4-cyclohexylene group),and k, m, n: each independently 0 or 1, provided that when k is 1 and L is -Cy-COO—, -Cy-OCO—, -E6-(CH2)2—, -E7-CH2O— or -E8-O—, at least one of m and n is 0. The present compound is useful for liquid crystal composition and optical element.
    Type: Grant
    Filed: December 26, 2006
    Date of Patent: October 28, 2008
    Assignee: Asahi Glass Company, Limited
    Inventors: Yuriko Kaida, Hiromichi Nagayama, Hiroshi Kumai
  • Patent number: 7427685
    Abstract: Therapeutic compounds according to one of the structures below are disclosed herein.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: September 23, 2008
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Robert M. Burk
  • Patent number: 7425603
    Abstract: A polymer comprising structural units derived from a polycyclic dihydroxy compound of Formula (I) wherein R1, R2 and R3 are independently at each occurrence selected from the group consisting of a cyano functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons, and an aromatic functionality having 6 to 10 carbons; wherein each occurrence of “n”, “m”, and “p” independently has a value of 0, 1, 2, 3, or 4; and wherein the polymer is substantially linear.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: September 16, 2008
    Assignee: General Electric Company
    Inventors: T. Tilak Raj, Radhakrishna Arakali Srinivasarao, Jan-Pleun Lens, Subrahmanya Bhat K., Umesh Hasyagar, Subash Scindia
  • Publication number: 20080139816
    Abstract: The present invention relates to a process for the preparation of compounds of formula (I), wherein the substituents are as defined in claim 1, by reacting a compound of formula (II), with a bromine or chlorine source to form a compound of formula (III), wherein X is chlorine or bromine; reacting that compound with water to form the compound of formula (IV), converting that compound, using a compound of formula (V), wherein M+ is the hydrogen cation or an alkali metal ion, alkaline earth metal ion or ammonium ion, into the compound of formula (VI), and treating that compound with a cyanide source in the presence of a base.
    Type: Application
    Filed: April 29, 2005
    Publication date: June 12, 2008
    Applicant: SYNGENTA CROP PROTECTION, INC.
    Inventors: David Anthony Jackson, Andrew Edmunds, Martin Charles Bowden, Ben Brockbank
  • Publication number: 20080116419
    Abstract: The instant invention relates to mesogenic media comprising one or more compounds which comprise two or more mesogenic groups two of which are linked to the ortho-positions of an aromatic ring, preferably of formula (I) wherein the parameters are as specified in the text, preferably the instant invention relates to mesogenic media showing a blue phase and their use in electro-optical light modulation elements and their respective use in displays, as well as to such devices. The instant invention further relates to compounds of formula (I).
    Type: Application
    Filed: December 22, 2005
    Publication date: May 22, 2008
    Applicant: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Gerald Unger, Andreas Ruhl, Michael Heckmeier, Peter Best, John Patrick
  • Publication number: 20070259929
    Abstract: Therapeutic substituted cyclopentane compounds, and compositions, medicaments, and therapeutic methods related thereto are disclosed herein.
    Type: Application
    Filed: April 27, 2007
    Publication date: November 8, 2007
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • Patent number: 7232821
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2, Rx, R8, R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: June 19, 2007
    Assignee: Glaxo Group Limited
    Inventors: Gerard Martin Paul Giblin, Adrian Hall, David Nigel Hurst, Ian Reginald Kilford, Xiao Qing Lewell, Alan Naylor, Riccardo Novelli
  • Patent number: 7037914
    Abstract: A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: May 2, 2006
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Hisao Tajima, Yoshisuke Nakayama, Daikichi Fukushima
  • Patent number: 6960681
    Abstract: The invention relates to novel and valuable intermediate compounds of the general formula (VIII) which can be used for the preparation of novel compounds comprising an antibacterial action, especially with a strong antibacterial action against helicobacter pylori, and pharmaceutically acceptable salts thereof. In the general formula (VIII) X is hydrogen or halogen, Y is hydrogen or a substituted or unsubstituted aralkyloxycarbonyl group having 8-19 carbon atoms, Z is hydrogen, a substituted aralkyloxycarbonyl group having 8-19 carbon atoms or a substituted alkoxycarbonyyl group having 2-19 carbon atoms, except that X, Y and Z are all hydrogen.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: November 1, 2005
    Assignee: Nagase ChemteX Corporation
    Inventors: Osamu Kamoda, Hiromichi Fujiwara, Toshiharu Yanagi
  • Patent number: 6909012
    Abstract: O-medium alkyl esters of diflunisal and related compounds are disclosed having anti-platelet activity, hydroxy radical scavenging properties, enhanced hepatic clearance and low ulcerogenic potential. These compounds have general formula (I) wherein n equals 3-13.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: June 21, 2005
    Assignee: University of Queensland
    Inventors: Daniel Yung-Yu Hung, Michael Stephen Roberts
  • Patent number: 6869967
    Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? suptype.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: March 22, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Paul Stanley Bury, John Patrick Mogensen, Ingrid Pettersson, Per Sauerberg
  • Patent number: 6831190
    Abstract: The invention relates to novel and valuable intermediate compounds of the general formula (VIII) which can be used for the preparation of novel compounds comprising an antibacterial action, especially with a strong antibacterial action against helicobacter pylori, and pharmaceutically acceptable salts thereof. In the general formula (VIII) X is hydrogen or halogen, Y is hydrogen or a substituted or unsubstituted aralkyloxycarbonyl group having 8-19 carbon atoms, Z is hydrogen, a substituted aralkyloxycarbonyl group having 8-19 carbon atoms or a substituted alkoxycarbonyyl group having 2-19 carbon atoms, except that X, Y and Z are all hydrogen.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: December 14, 2004
    Assignee: Teikoku Chemical Industries Co., Ltd.
    Inventors: Osamu Kamoda, Hiromichi Fujiwara, Toshiharu Yanagi
  • Patent number: 6762315
    Abstract: The invention relates to a method for producing [1,1′:4′,1″]-terphenyl compounds of the formula which comprises reacting a metal aryl of the formula with a boric ester at −80 to 40° C. in the presence of an inert solvent, converting the reaction product by hydrolysis into a boronic acid of the formula reacting the boronic acid, a boronic anhydride obtainable from boronic acid by elimination of water, or a mixture of boronic acid and boronic anhydride, with an alcohol, and reacting the boronic ester formed thereby with a biphenyl compound of the formula at 40 to 180° C. in the presence of a catalyst, of an acid-binding agent and of a polar solvent.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: July 13, 2004
    Assignee: Clariant GmbH
    Inventors: Stefan Scherer, Steffen Haber
  • Patent number: 6677475
    Abstract: Optically active compounds of the following general formula (1) useful as chiral dopant, wherein n is an integer of 0 to 5, provided that when n is 0, A is a single bond (—) and that when n is 1 to 5, A is a single bond (—), —O—, —COO—, —Cy— or —Cy—COO— in which —Cy— is a trans-1,4-cyclohexylene group, each of X and Y is independently a hydrogen atom or a fluorine atom, B is a single bond (—), —COO—, —COO—Ph— or —Ph—COO— in which —Ph— is a 1,4-phenylene group, and C* is an asymmetric carbon. The chiral dopant of the present invention have a high helical twisting power of at least 9 and suitably have a feature that the helical pitch induced by them decreases in length with an increase in temperature so that they are advantageous for use in a nematic liquid crystal composition.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: January 13, 2004
    Assignee: Mitsubishi Gas Chemical Co., Inc.
    Inventors: Yasumasa Norisue, Takakiyo Mine, Masahiro Johno
  • Patent number: 6653499
    Abstract: Compounds of formula (I) may be used as alignment layers in liquid crystal devices wherein X1-5 are idependently selected from H, F, CN, phenylene, C1-10 alkyl, whereby when X1=X2, then X1,2=H and when X3=X4, then X3,4=H, S1-3 are spacer units, PG1-3 are photoisomerisable/dimerisable groups.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: November 25, 2003
    Assignee: Qinetiq Limited
    Inventors: Alan W Hall, Stephen M Kelly, Gareth J Owen, Ridvan Karapinar, Mary O'Neill
  • Patent number: 6627656
    Abstract: This invention encompasses a method for the treatment or prevention of prostaglandin mediated diseases comprising administering to a mammalian patient a compound of formula I: in an amount that is effective to treat or prevent said prostaglandin mediated disease. Novel compounds are also disclosed.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: September 30, 2003
    Inventors: Michel Gallant, Nicolas Lachance, Marc Labelle, Robert Zamboni, Helene Juteau, Yves Gareau, Patrick Lacombe
  • Patent number: 6596193
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electrooptical system. The electrooptical system comprises a PDLC film comprising a liquid crystal mixture forming micro- droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers. The reactive liquid crystalline compounds are of formula II, R′—G′—R″, wherein R′, G′ and R″ are as defined herein. The liquid crystal mixture comprises one or more compounds of the formula I wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: July 22, 2003
    Assignee: Merck Patent GmbH
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Patent number: 6565769
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electrooptical system. The electrooptical system comprises a PDLC film comprising a liquid crystal mixture forming micro- droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers, one of the refractive indices of the liquid crystal mixture is matched to the refractive index of the polymer matrix, the PDLC film exhibits an electrically switching transparency essentially independent of the polarization of the incident light, the precursor of the PDLC film comprises one or more monomers, oligomers and/or prepolymers and a photoinitiator, and is cured photoradically, the liquid crystal mixture comprises one or more compounds of the formula I  wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: May 20, 2003
    Assignee: Merck Patent GmbH
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Patent number: 6555577
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: April 29, 2003
    Assignee: Novo Nordisk A/S
    Inventors: John Patrick Mogensen, Per Sauerberg, Paul Stanley Bury, Lone Jeppesen, Ingrid Pettersson
  • Patent number: 6518306
    Abstract: This invention relates to compounds of Formula (I) where Z is an amine, alcohol or derivative thereof, and the ketone analog thereof.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: February 11, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Siegfried B. Christensen, IV
  • Patent number: 6515021
    Abstract: The invention relates to novel bicyclic aromatic compounds which have the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: February 4, 2003
    Assignee: Centre International de Recherches Dermatologiques Galderma
    Inventor: Jean-Michel Bernardon
  • Patent number: 6452022
    Abstract: This invention relates to a method of preparing a compound type where at least one of R′ or R″ is a carboxyl group (I) by treating a compound of formula (II) with a Group I(a) or Group II(a) metal halide, with an aprotic dipolar amide-based solvent and water.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: September 17, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Kevin Webb, Wilford Mendelson, Jianhao Chen
  • Patent number: 6376546
    Abstract: Compounds represented by general formula I or salts thereof, wherein n is an integer of 2 or 3; R represents a straight-chain or branched saturated alkyl group having 4 or 4 carbon atoms, a cyclopentyl group, a cyclohexyl group or the like, Y represents a hydroxyl or amino group, A represents a hydrogen atom, a hydroxyl, methoxy, nitro group or the like, Q represents a hydrogen atom or a hydroxyl or methoxy group. They can be formulated to give pharmaceutical compositions that are effective as prophylactic or therapeutic agents for allergic diseases associated with IgE production inhibitors or IgE antibodies.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: April 23, 2002
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventors: Motoshi Shoda, Hiromichi Itoh
  • Patent number: 6369261
    Abstract: Compounds having Formula 2 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: April 9, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Alan T. Johnson, Jayasree Vasudevan, Liming Wang, Roshantha A. Chandraratna
  • Patent number: 6337408
    Abstract: This invention relates to a method of preparing a compound of the following type by treating a compound of formula (II) with lithium bromide, magnesium bromide and the like.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: January 8, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Andrew Allen, Ann Marie Diederich, Li Liu, Wilford Mendelson, Kevin Webb
  • Patent number: 6326397
    Abstract: The present invention relates to novel retinoid antagonists of the formula I wherein the dotted bond can be either hydrogenated or form a double bond; and, when the dotted bond forms a double bond, R1 is lower alkyl and R2 is hydrogen; and, when the dotted bond is hydrogenated, R1 and R2 taken together are methylene to form a cis-substituted cyclopropyl ring; R3 is hydroxy or lower alkoxy; R4 is alkyl or alkoxy; and R5 and R6 are, independently, a C4-12 alkyl or a 5-12 cycloalkyl substituent containing from 1-3 rings which are either unsubstituted or substituted with from 1-3 lower alkyl groups, with the carbon atom of R5 and R6 being linked to the remainder of the molecule to form a quaternary carbon atom pharmaceutically acceptable salts of carbocylic acids of the formula I; as well as method for the treatment of osteoporosis and preneoplastic and neoplastic diseases, and a method for reducing or abolishing adverse events in subjects receiving retinoid agonist treatment by administering a
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: December 4, 2001
    Assignee: Hoffman-La Roche Inc.
    Inventors: Werner Bollag, Michael Klaus, Peter Mohr, Paola Panina-Bordignon, Michael Rosenberger, Francesco Sinigaglia
  • Patent number: 6307089
    Abstract: Biphenyl butyric acid compounds and derivatives are described as well as acid methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: October 23, 2001
    Assignee: Warner-Lambert Company
    Inventors: Claude Forsey Purchase, Jr., Bruce David Roth, Gerald Paul Schielke, Lary Craswell Walker, Andrew David White
  • Patent number: 6242636
    Abstract: An electoclinic device having two spaced cell walls each bearing electrode structures and treated on at least one facing surface with an alignment layer, a layer of a smectic liquid crystal material enclosed between the cell walls, where the liquid crystal material contains one or more of the compounds described by formula I as defined in the specification.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: June 5, 2001
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britian and Northern Ireland of Defence Evaluation and Research Agency
    Inventors: Andrew John Slaney, Damien Gerard McDonnell, Amarjit Kaur Samra, Maurice Stanley, Victoria Minter, John William Goodby, Michael Hird, Simon John Cross, Chu Chuan Dong
  • Patent number: 6172239
    Abstract: The invention relates to compounds of the formula The compounds have agreat affinity for the neurotensin receptors.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: January 9, 2001
    Assignee: Sanofi
    Inventors: Bernard Labeeuw, Danielle Gully, Francis JeanJean, Jean-Charles Molimard, Robert Boigegrain
  • Patent number: 6147111
    Abstract: Novel phenyl derivatives which are useful as endothelin receptor antagonists.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: November 14, 2000
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham Corporation
    Inventors: Jia-Ning Xiang, David Timothy MacPherson, David Francis Corbett, John Duncan Elliott
  • Patent number: 6147255
    Abstract: The invention relates to novel bicyclic aromatic compounds which have the general formula (I): ##STR1## as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: November 14, 2000
    Assignee: Centre International de Recherches Dermatologiques Galderma
    Inventor: Jean-Michel Bernardon